Corporate Board Profile
Tech Score: 0/100
Filing Date | Source Excerpt |
---|---|
2016-04-11 | Glenn P. Muir has served as a director of Repligen and a member of its Audit Committee since October 2015. ... The Audit Committee currently consists of Mr. Ryan, Chairperson, Mr. Cox and Mr. Muir. ... The Compensation Committee, of which Dr. Cooper, Mr. Barthelemy and Mr. Muir (effective as of October 2015) are currently members ... Director Compensation Table for the Fiscal Year Ended December 31, 2015 ... Glenn P. Muir Fees Earned or Paid in Cash($) 17,295, Stock Awards($) 0, Option Awards($) 453,494, Total($) 470,789. |
2017-04-21 | Glenn P. Muir has served as a director of Repligen and a member of its Audit Committee since October 2015. ... Mr. Muir also serves on the boards of medical device company ReWalk Robotics Ltd. and life science company G1 Therapeutics, Inc. ... The Audit Committee currently consists of Mr. Muir, Chairperson, Mr. Cox and Mr. Ryan. ... The Compensation Committee, of which Dr. Cooper, Mr. Barthelemy and Mr. Muir are currently members ... Director Compensation Table for the Fiscal Year Ended December 31, 2016 ... Glenn P. Muir 72,778 46,050 46,476 165,304 |
2018-04-20 | Glenn P. Muir has served as a director of Repligen since October 2015. Mr. Muir brings over 30 years of experience to the director role, including 26 years with Hologic, Inc., a large multi-national medical device and diagnostics company where he most recently served as Chief Financial Officer and Executive Vice President, Finance and Administration. ... Mr. Muir also serves on the boards of medical device company Neuronetics, Inc. Mr. Muir also serves on the board of directors of the following publicly-traded companies: G1 Therapeutics, Inc. and ReWalk Robotics Ltd. ... Mr. Muir's qualifications to sit on Repligen's Board of Directors include his extensive experience with integrating strategic acquisitions and leading the financial operations for a global manufacturing and commercial organization. |
2019-04-18 | Glenn P. Muir has served as a director of Repligen since October 2015. ... Mr. Muir serves on the board of directors of Neuronetics, Inc. and life science company G1 Therapeutics, Inc. ... Mr. Muir is Chairperson of the Audit Committee and a member of the Compensation Committee. ... Director Compensation Table for the Fiscal Year Ended December 31, 2018: Glenn P. Muir Total Compensation: $215,370. |
2020-04-28 | Glenn P. Muir has served as a director of Repligen since October 2015. Mr. Muir brings over 30 years of experience to the director role, including 26 years with Hologic, Inc., a large multi-national medical device and diagnostics company where he most recently served as Chief Financial Officer and Executive Vice President. |
2021-04-21 | Glenn P. Muir has served as a director of Repligen since October 2015. Mr. Muir retired as Chief Financial Officer and Executive Vice President of Hologic, Inc. He serves as Chairperson of the Audit Committee and is a member of the Compensation Committee. |
2022-04-11 | Glenn P. Muir has served as a director of Repligen since October 2015. ... Mr. Muir retired in May 2014 from Hologic, where he helped steer the company’s evolution from a venture-backed single product company to a publicly traded diversified organization with over 5,000 employees and $2.5 billion in revenue. ... Mr. Muir currently serves as Chairperson of the Audit Committee. ... Director Compensation Table for the Fiscal Year Ended December 31, 2021 shows total compensation $250,051. |
2023-04-11 | Glenn P. Muir Retired Chief Financial Officer and Executive Vice President, Hologic, Inc. 64 2015 ✓ 2 CHAIR • 100,000 84,997 85,000 269,997 |
2024-04-01 | Glenn P. Muir has served as a director of Repligen since October 2015. Mr. Muir brings over 30 years of experience to the director role. |
2025-04-04 | Mr. Muir is a Certified Public Accountant (inactive since 2022) with a B.A. from the University of Massachusetts, Amherst. He also earned a M.S. in Taxation from Bentley University and a M.B.A. from Harvard University. |
Data sourced from SEC filings. Last updated: 2025-08-30